Similar to the therapeutic action of MS, GO suppressed colonic weight gain, myeloperoxidase (MPO) activity, and significantly reduced malondialdehyde (MDA), TNF-α and IL-1β levels. The gene discussed is MPO; the disease is myeloid sarcoma.